Nomogram Models to Predict Postoperative Hyperlactatemia in Patients Undergoing Elective Cardiac Surgery

Dashuai Wang1†, Su Wang2†, Jia Wu3†, Sheng Le1†, Fei Xie4†, Ximei Li5, Hongfei Wang1, Xiaofan Huang1*, Xinling Du1* and Anchen Zhang6*

1 Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, 2 Department of Emergency Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, 3 Key Laboratory for Molecular Diagnosis of Hubei Province, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, 4 Department of Cardiovascular Surgery, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China, 5 Department of Nursing, Huaie Hospital of Henan University, Kaifeng, China, 6 Department of Cardiology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Objectives: Postoperative hyperlactatemia (POHL) is common in patients undergoing cardiac surgery and is associated with poor outcomes. The purpose of this study was to develop and validate two predictive models for POHL in patients undergoing elective cardiac surgery (ECS).

Methods: We conducted a multicenter retrospective study enrolling 13,454 adult patients who underwent ECS. All patients involved in the analysis were randomly assigned to a training set and a validation set. Univariate and multivariate analyses were performed to identify risk factors for POHL in the training cohort. Based on these independent predictors, the nomograms were constructed to predict the probability of POHL and were validated in the validation cohort.

Results: A total of 1,430 patients (10.6%) developed POHL after ECS. Age, preoperative left ventricular ejection fraction, renal insufficiency, cardiac surgery history, intraoperative red blood cell transfusion, and cardiopulmonary bypass time were independent predictors and were used to construct a full nomogram. The second nomogram was constructed comprising only the preoperative factors. Both models showed good predictive ability, calibration, and clinical utility. According to the predicted probabilities, four risk groups were defined as very low risk (<0.05), low risk (0.05–0.1), medium risk (0.1–0.3), and high risk groups (>0.3), corresponding to scores of ≤180 points, 181–202 points, 203–239 points, and >239 points on the full nomogram, respectively.

Conclusions: We developed and validated two nomogram models to predict POHL in patients undergoing ECS. The nomograms may have clinical utility in risk estimation, risk stratification, and targeted interventions.

Keywords: cardiac surgery, postoperative hyperlactatemia, prediction model, nomogram, risk factor
INTRODUCTION

Postoperative hyperlactatemia (POHL) is a common metabolic disorder in patients undergoing cardiac surgery and is associated with adverse clinical outcomes, such as severe acute kidney injury, acute respiratory distress syndrome, and mortality (1–3). Given that elevated lactate levels have important implications for poor prognosis, lactate levels could represent a useful goal of initial resuscitation (4). Nonetheless, studies on lactate-directed therapy performed in post-cardiac surgery patients are limited (5). The reported incidence of POHL in different studies varied greatly, from 11.1 to 45.6% (6, 7).

Globally, numerous studies have been conducted to explore predictors for POHL after cardiac surgery due to its high prevalence and poor outcomes (8–10). Some significant risk factors have been reported in the literature, such as non-elective surgery and diabetes mellitus (8, 11). However, the baseline characteristics of the surgical patients have changed substantially these years due to great advances in anesthesia and surgical techniques. Many studies were published decades ago, and some conclusions may have been obsolete because of the very limited samples and narrow patient selection (3, 12). In addition, the majority of the published studies were conducted in patients undergoing mixed surgeries or single valvular heart surgery (13, 14), but none were conducted specifically for patients undergoing elective cardiac surgery (ECS). To our knowledge, a large-scale persuasive study on this topic is still lacking, and the establishment of a convincing prediction model is still an urgent need.

The aim of this study was to identify independent risk factors for the development of POHL in adult patients who underwent ECS and to develop and validate two easy-to-use clinical prediction models that may help clinicians evaluate the risk of POHL and implement appropriate interventions early.

METHODS

Ethical Statement

This study was conducted according to the ethical statement of the Declaration of Helsinki and was approved by the ethical committee of the Union Hospital (No. 0521), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Individual consent was waived due to the retrospective nature.

Study Design and Patient Population

We conducted a multicenter retrospective study consisting of all the adult patients (age ≥ 18 years) who were admitted to the intensive care unit (ICU) after ECS, at four tertiary care academic centers for a period of 5 years from January 2016 to December 2020. Exclusion criteria were patients who experienced emergency cardiac surgery, organ transplantation, immunosuppression or immune deficiency, and intraoperative death.

The following information was collected: age, sex, body mass index, drinking history, smoking history, hypertension, diabetes mellitus, chronic obstructive pulmonary disease, general surgery history, cardiac surgery history, peripheral vascular disease, cerebrovascular disease, gastrointestinal tract disease, renal insufficiency, atrial fibrillation, pericardial effusion, left ventricular ejection fraction (LVEF), New York Heart Association class, pulmonary artery hypertension; white blood cell count, red blood cell (RBC) count, hemoglobin, serum albumin, globulin, and creatinine; aortic cross-clamp time, cardiopulmonary bypass time, and intraoperative transfusion of RBC.

Outcomes

The primary outcome was the occurrence of POHL in patients undergoing ECS. The secondary outcomes were readmission to ICU, in-hospital mortality, the length of ICU, and hospital stay.

Measurement and Definition

Lactate was routinely measured from ICU admission to ICU discharge in these hospitals. Based on clinical practice and previous literature, POHL was defined as lactate level > 4 mmol/L in this study (15, 16). All the available lactate values within the first 12 h after ICU admission were recorded, and the peak values were used to identify the presence or absence of POHL.

Statistical Analysis

Descriptive statistics were used to summarize baseline data of the study population. Continuous variables were presented as means with standard deviations when normally distributed and medians with interquartile ranges when non-normally distributed. Categorical variables were expressed as frequencies with percentages. Missing values were imputed by applying multiple imputations. We first performed a univariate analysis to screen possible risk factors. Student’s t-test, a non-parametric test, Chi-square test, and Fisher’s exact test were used as appropriate. Variables with \( p < 0.1 \) were further analyzed to identify independent predictors by forwarding stepwise multivariate logistic regression. Results from logistic regression analysis were expressed as odds ratios (ORs) with 95% CIs. A nomogram based on the multivariate model was then established.

Internal validation of the nomogram model was evaluated by bootstrapping using 1,000 replications. External validation was performed in an independent validation cohort. To assess the calibration of the model, a smoothed non-parametric calibration curve and a fitted logistic calibration curve were depicted. To evaluate the discrimination of the model, the area under the receiver operating characteristic (ROC) curve (AUC) or the c-index was calculated. To assess the clinical utility of the model, a decision curve analysis was performed. The decision curve was used to quantify the clinical utility of the model, displaying standardized net benefit against risk threshold probability. The clinical impact curve showed the number of judged high-risk patients for different threshold probabilities and the number of true positives. To analyze the relationship...
A multivariate model was constructed. By multivariate logistic regression analysis, six independent predictors associated with the development of POHL after ECS were identified, including age, LVEF, renal insufficiency, cardiac surgery history, the volume of intraoperative RBC transfusion, and CPB time (Table 3). Based on these independent predictors, a full nomogram was established to predict the risk of POHL after ECS (Figure 2). Regression coefficients of the variables were correspondingly established to predict the risk of POHL after ECS (Table 3). The average age of these patients was 51.59 ± 13.16 years and the proportion of men was 53.9%. The overall incidence of POHL after ECS was 10.6%. All the preoperative and intraoperative variables were well-balanced between the two sets (Table 1).

### RESULTS

#### Demographic Characteristic

Among the 15,207 adult patients who underwent cardiac surgery, 1,189 patients underwent emergency procedures, 548 patients experienced organ transplantation, immunosuppression, or immune deficiency, and 16 patients died intraoperatively. The remaining 13,454 patients fulfilling the inclusion criteria were randomly assigned to a training set (n = 7,802) and a validation set (n = 5,652), and were further analyzed (Figure 1). The average age of these patients was 51.59 ± 13.16 years and the proportion of men was 53.9%. The overall incidence of POHL after ECS was 10.6%. All the preoperative and intraoperative variables were well-balanced between the two sets (Table 1).

#### Construction of a Full Nomogram for POHL

A total of 829 patients developed POHL after ECS in the training set. The possible risk factors for POHL are displayed in Table 2. Collinearity diagnostics were performed before the multivariate model was constructed. By multivariate logistic regression analysis, six independent predictors associated with the development of POHL after ECS were identified, including age, LVEF, renal insufficiency, cardiac surgery history, the volume of intraoperative RBC transfusion, and CPB time (Table 3). Based on these independent predictors, a full nomogram was established to predict the risk of POHL after ECS (Figure 2). Regression coefficients of the variables were correspondingly established to predict the risk of POHL after ECS (Table 3).

### Table 1 | Comparison of characteristics between the training and validation sets.

| Characteristic | Training set | Validation set | P-value |
|---------------|--------------|----------------|---------|
| Demographics  |              |                |         |
| Age (years)†  | 51.58 ± 13.15| 51.60 ± 13.16  | 0.946   |
| Male‡         | 4,203 (53.9) | 3,053 (54.0)   | 0.867   |
| Body mass index (kg/m²)‡ | 23.14 ± 3.29 | 23.10 ± 3.30 | 0.475   |
| Smoking‡      | 2,109 (27.0) | 1,525 (27.0)   | 0.949   |
| Drinking‡     | 1,551 (19.9) | 1,160 (20.5)   | 0.358   |
| Underlying conditions |          |                |         |
| Hypertension‡ | 1,939 (24.9) | 1,411 (25.0)   | 0.882   |
| Diabetes mellitus‡ | 594 (7.6) | 465 (8.2)     | 0.192   |
| Chronic obstructive pulmonary disease‡ | 882 (11.7) | 660 (11.7) | 0.503   |
| Renal insufficiency§ | 564 (7.2) | 413 (7.3) | 0.863   |
| Gastrointestinal tract disease§ | 647 (8.3) | 455 (8.1) | 0.613   |
| Atrial fibrillation§ | 1,542 (19.8) | 1,066 (16.9) | 0.191   |
| General surgery history§ | 2,243 (28.7) | 1,680 (29.7) | 0.219   |
| Cardiac surgery history§ | 537 (6.9) | 392 (6.9) | 0.905   |
| New York Heart Association class III-IV§ | 1,342 (17.2) | 946 (16.7) | 0.480   |
| Pulmonary artery hypertension§ | 2,278 (29.2) | 1,642 (29.1) | 0.854   |
| Pericardial effusion§ | 1,005 (12.9) | 746 (12.3) | 0.589   |
| Left ventricular ejection fraction (%)§ | 62 (57, 67) | 62 (57, 67) | 0.985   |
| Laboratory values |          |                |         |
| White blood cell count (× 10⁹/L)* | 5.7 (4.7, 6.8) | 5.7 (4.7, 6.8) | 0.397   |
| Red blood cell count (× 10¹²/L)* | 4.3 (3.9, 4.7) | 4.3 (3.9, 4.7) | 0.687   |
| Hemoglobin (g/L)* | 130 (118, 141) | 129 (118, 141) | 0.579   |
| Serum creatinine (µmol/L)* | 71.0 (60.3, 83.8) | 71.0 (60.3, 83.8) | 0.364   |
| Serum albumin (g/L)§ | 40.53 ± 3.83 | 40.64 ± 3.79 | 0.100   |
| Serum globulin (g/L)§ | 24.66 ± 4.41 | 24.63 ± 4.35 | 0.653   |
| Operative variables |          |                |         |
| Cardiopulmonary bypass time (minutes)* | 100 (77, 130) | 100 (76, 128) | 0.093   |
| Aortic cross clamp time (minutes)* | 67 (48, 89) | 67 (47, 88) | 0.147   |
| Intraoperative transfusion of RBC (units)* | 1 (0, 3) | 1 (0, 3) | 0.402   |

† Normally distributed continuous variables are presented as means with standard deviations and analyzed by Student’s t-test.

‡ Non-normally distributed continuous variables are presented as medians with interquartile ranges and analyzed by non-parametric test.

§ Categorical variables are presented as frequencies with percentages and analyzed by Chi-square test or Fisher’s exact test. RBC, red blood cell.
### TABLE 2 | Univariate analysis of risk factors for POHL after elective cardiac surgery in the training set.

| Characteristic                          | Without POHL | With POHL | $\chi^2/Z/t$ | P-value |
|----------------------------------------|--------------|-----------|--------------|---------|
| Demographics                           |              |           |              |         |
| Age (years)†                           | 50.93 ± 13.16| 57.02 ± 11.83| 13.829       | <0.001  |
| Male§                                  | 3,698 (53.0) | 505 (60.9) | 18.531       | <0.001  |
| Body mass index (kg/m²)†               | 23.13 ± 3.31 | 23.17 ± 3.06  | 0.334        | 0.739   |
| Smoking§                               | 1,831 (26.3) | 278 (33.5)  | 19.886       | <0.001  |
| Drinking§                              | 1,345 (19.3) | 206 (24.8)   | 14.383       | <0.001  |
| Underlying conditions                  |              |           |              |         |
| Hypertension§                          | 1,660 (23.8) | 279 (33.7)  | 38.482       | <0.001  |
| Diabetes mellitus§                     | 539 (7.7)    | 55 (6.6)   | 1.264        | 0.261   |
| Chronic obstructive pulmonary disease§ | 755 (10.8)   | 127 (15.3)  | 14.911       | <0.001  |
| Cerebrovascular disease§               | 1,200 (17.2) | 190 (22.9)  | 16.498       | <0.001  |
| Peripheral vascular disease§           | 1,437 (20.6) | 241 (29.1)  | 31.435       | <0.001  |
| Renal insufficiency§                   | 412 (5.9)    | 152 (18.3)  | 170.610      | <0.001  |
| Gastrointestinal tract disease§        | 566 (8.1)    | 81 (9.8)    | 2.655        | 0.103   |
| Atrial fibrillation§                   | 1,308 (18.8) | 234 (28.2)  | 41.889       | <0.001  |
| General surgery history§               | 2,037 (29.2) | 206 (24.8)  | 8.887        | 0.009   |
| Cardiac surgery history§               | 401 (5.8)    | 136 (16.4)  | 131.232      | <0.001  |
| New York Heart Association class III-IV§ | 1,136 (16.3) | 206 (24.8)  | 38.100       | <0.001  |
| Pulmonary artery hypertension§         | 2,047 (29.4) | 231 (27.9)  | 0.797        | 0.372   |
| Pericardial effusion§                  | 907 (13.0)   | 98 (11.8)   | 0.928        | 0.335   |
| Left ventricular ejection fraction (%)* | 62 (58, 67)  | 60 (53, 65) | 11.102       | <0.001  |
| Laboratory values                      |              |           |              |         |
| White blood cell count (×10⁹/L)*       | 5.7 (4.7, 6.8)| 5.7 (4.9, 6.7)| 0.775        | 0.438   |
| Red blood cell count (×10¹²/L)*        | 4.3 (3.9, 4.7)| 4.3 (4.0, 4.6)| 0.574        | 0.566   |
| Hemoglobin (g/L)*                      | 130 (118, 141)| 130 (119, 141)| 0.260        | 0.795   |
| Serum creatinine (µmol/L)*             | 70.9 (60.3, 83.5)| 75.7 (63.4, 90.4)| 6.781        | <0.001  |
| Serum albumin (g/L)*                   | 40.58 ± 3.87 | 40.16 ± 3.52 | 3.191        | 0.001   |
| Serum globulin (g/L)*†                 | 24.65 ± 4.37 | 24.77 ± 4.70 | 0.713        | 0.476   |
| Operative variables                    |              |           |              |         |
| Cardiopulmonary bypass time (minutes)* | 97 (75, 126) | 132 (102, 167)| 19.953       | <0.001  |
| Aortic cross clamp time (minutes)*     | 66 (46, 87)  | 83 (63, 112)| 15.107       | <0.001  |
| Intraoperative transfusion of RBC (units)* | 1 (0, 2.5) | 3 (1, 6)   | 17.825       | <0.001  |

† Normally distributed continuous variables are presented as means with standard deviations and analyzed by Student’s t-test.

*Non-normally distributed continuous variables are presented as medians with interquartile ranges and analyzed by non-parametric test.

§Categorical variables are presented as frequencies with percentages and analyzed by the chi-square test or Fisher’s exact test. POHL, postoperative hyperlactatemia; RBC, red blood cell.

### TABLE 3 | Multivariate analysis of independent risk factors for postoperative hyperlactatemia after elective cardiac surgery.

| Characteristic                          | Coefficient | Standard error | OR (95% CI) | P-value |
|----------------------------------------|-------------|----------------|-------------|---------|
| Age (years)                            | 0.028       | 0.004          | 1.029 (1.021–1.036) | <0.001  |
| Renal insufficiency                    | 0.695       | 0.117          | 2.003 (1.592–2.520) | <0.001  |
| Cardiac surgery history                | 1.125       | 0.123          | 3.079 (2.418–3.922) | <0.001  |
| Left ventricular ejection fraction (%)* | −0.050      | 0.004          | 0.951 (0.943–0.960) | <0.001  |
| Cardiopulmonary bypass time (minutes)  | 0.013       | 0.001          | 1.013 (1.011–1.015) | <0.001  |
| Transfusion of red blood cell (units)   | 0.191       | 0.017          | 1.210 (1.170–1.252) | <0.001  |
| Intercept                              | −2.921      | 0.346          | 0.054        | <0.001  |

CI, confidence interval; OR, odds ratio.
converted to scores within a range of 0–100, reflecting their relative importance. The probability of POHL in a patient can be calculated easily by summing the points of all these predictors. A true case is presented in Figure 2.

Validation and Assessment of the Full Nomogram
The full nomogram was validated by using both internal and external validation. The calibration was tested by both visual inspections of the calibration plots and the goodness-of-fit test. The full nomogram was well-calibrated in both the training (Hosmer–Lemeshow $\chi^2 = 3.72, p = 0.881$) and the validation (Hosmer–Lemeshow $\chi^2 = 6.86, p = 0.551$) sets. By visual inspection, the full nomogram also showed good calibration (Figures 3A,B). To evaluate the predictive performance of the full nomogram, the ROC curves were drawn in both sets (Figure 3C). The AUC was 0.799 (95% CI, 0.783–0.815) in the training set and 0.802 (95% CI, 0.783–0.820) in the validation set, respectively. No significant difference was found between the two AUCs ($p = 0.838$). To assess the clinical utility, a decision curve analysis was performed. Compared with “no intervention” or “intervention for all” strategies, the use of the full nomogram could obtain more clinical net benefits when the risk threshold was between 0.07 and 0.61 (Figure 3D). The clinical impact curves also showed that the number of deemed high risk to develop POHL and the number of patients with actual POHL events tended to be close within this risk threshold, indicating prominent predictive power, and good clinical utility (Figures 3E,F).

Establishment, Validation, and Assessment of a Preoperative Prediction Model
To facilitate clinical application, a second nomogram model was established using only preoperative variables. Age, LVEF, renal insufficiency, and cardiac surgery history were identified as independent risk factors for POHL in patients undergoing ECS by multivariate logistic regression analysis (Table 4). A preoperative nomogram model was then constructed based on these four preoperative predictors (Figure 4A). This model was also well-calibrated in the training (Hosmer–Lemeshow $\chi^2 = 4.16, p = 0.842$) and validation (Hosmer–Lemeshow $\chi^2 = 7.11, p = 0.525$) sets (Figures 4B,C). The AUCs were, respectively, 0.723 (95% CI, 0.705–0.741) and 0.729 (95% CI, 0.708–0.750) in the training and validation sets (Figure 4D), and there was no significant difference between the two AUCs ($p = 0.688$). More clinical net benefits could be obtained using this...
Wang et al. Nomogram for Postoperative Hyperlactatemia

FIGURE 3 | Assessment and validation of the full nomogram model. (A) calibration plot in the training set; (B) calibration plot in the validation set; (C) ROC curves in both the training and validation sets; (D) decision curves in both the training and validation sets; (E) clinical impact curve in the training set; and (F) clinical impact curve in the validation set. AUC, area under the receiver operating characteristic curve; CI, confidence interval; ROC curve, receiver operating characteristic curve.

TABLE 4 | Multivariate analysis of preoperative predictors for postoperative hyperlactatemia after elective cardiac surgery.

| Characteristic                      | Coefficient | Standard error | OR (95% CI) | P-value |
|------------------------------------|-------------|----------------|-------------|---------|
| Age (years)                        | 0.040       | 0.003          | 1.040 (1.033–1.047) | <0.001 |
| Renal insufficiency                | 0.963       | 0.109          | 2.620 (2.115–3.244) | <0.001 |
| Cardiac surgery history            | 1.340       | 0.114          | 3.821 (3.057–4.776) | <0.001 |
| Left ventricular ejection fraction (%) | −0.046     | 0.004          | 0.955 (0.947–0.963) | <0.001 |
| Intercept                          | −1.737      | 0.313          | 0.176       | <0.001 |

CI, confidence interval; OR, odds ratio.

nomogram when the risk threshold was between 0.08 and 0.42, and it also showed good predictive power and clinical utility (Figures 4E–G).

Risk Intervals of POHL

Based on the full nomogram model and clinical practice, we stratified the study population into four-risk intervals, named very low risk, low risk, medium risk, and high risk groups (Table 5). The estimated probabilities of <5% were considered as very low-probability events and thus we chose 5% as a cutoff value to divide the very low risk and low risk groups. The estimated probabilities of between 5 and 10% were considered as low risk, 10–30% as medium risk, and >30% as high risk, respectively. The corresponding cutoff values on the nomogram were, respectively, ≤180, 181–202, 203–239, and >239 points. In this study, 43.1% of the patients were classified into the very low risk group, 24.9% into the low risk group, 24.7% into the medium risk group, and only 7.3% into the high risk group. Estimated probabilities and observed probabilities in the training and validation sets of the four risk intervals are presented in Figure 5, indicating good consistency in the same risk interval and significant differences among different risk intervals.
FIGURE 4 | Development, assessment, and validation of the preoperative nomogram model. (A) Preoperative nomogram predicting the development of postoperative hyperlactatemia in patients undergoing elective cardiac surgery; (B) calibration plot in the training set; (C) calibration plot in the validation set; (D) ROC curves in both the training and validation sets; (E) decision curves in both the training and validation sets; (F) clinical impact curve in the training set; (G) clinical impact curve in the validation set. AUC, area under the receiver operating characteristic curve; CI, confidence interval; LVEF, left ventricular ejection fraction; ROC curve, receiver operating characteristic curve.

TABLE 5 | Risk intervals of postoperative hyperlactatemia based on the full nomogram model.

| Risk intervals | Very low risk (<180 points) | Low risk (181–202 points) | Medium risk (203–239 points) | High risk (>239 points) |
|----------------|------------------------------|-----------------------------|------------------------------|-------------------------|
| Estimated probability (%) | <5 | 5–10 | 10–30 | >30 |
| Observed probability, % (95% CI) | 2.6 (2.2–3.0) | 8.0 (7.1–8.9) | 16.1 (14.9–17.4) | 48.3 (45.2–51.4) |
| No. of patients (%) | 5,792 (43.1) | 3,354 (24.9) | 3,320 (24.7) | 988 (7.3) |

CI, confidence interval.
Postoperative hyperlactatemia after ECS developed in 1,430 of the 13,454 patients (10.6%). By univariate analysis, we observed significantly poorer outcomes in patients with POHL compared with patients without that (Table 6). A total of 306 patients (2.3%) died in our results; however, the mortality was significantly higher in patients with POHL. To identify whether POHL was independently associated with a higher risk of readmission to ICU and mortality, we further conducted multivariate logistic regression analysis. We found that POHL was an independent predictor for both of the two outcomes, and patients with POHL had a 2.13-fold increased risk of readmission to ICU ($p < 0.001$) and a 2.34-fold increased risk of mortality ($p < 0.001$). To evaluate the influence of POHL on the lengths of ICU and hospital stay, we further performed propensity score matching by nearest-neighbor matching without replacement with an algorithm of 1:1 matching, yielding 1,350 matched pairs of patients. In this study population, the length of ICU stay in patients with and without POHL was, respectively, 4 (3, 7) and 4 (2, 6) days ($Z = 7.082, p < 0.001$) and the length of hospital stay in patients with and without POHL was, respectively, 17 (13, 23) and 16 (11, 20) days ($Z = 6.258, p < 0.001$).

**DISCUSSION**

The elevated level of postoperative lactate has been well-recognized to be associated with poor outcomes (1, 10, 14), which was confirmed again by the results of this study. The incidence of POHL after ECS was 10.6%, close to previous reports (6, 7). The overall mortality was 2.3%, which was confirmed again by the results of this study. The incidence of POHL after ECS was 10.6%, close to previous reports (6, 7). The overall mortality was 2.3%, which was confirmed again by the results of this study.
optimal management of patients with POHL is little known (17), emphasizing the importance of early management of high risk populations that may develop POHL.

To our knowledge, our study represents the first large-scale study that focuses on the risk factors for POHL after ECS and the establishment of nomogram models globally. In this study, we developed and validated two nomogram models for POHL after ECS using data from 13,454 patients in four institutions. By univariate and multivariate analysis, we identified four preoperative and two intraoperative independent risk factors for POHL. A full nomogram model based on all the six predictors and a preoperative nomogram model based on the four preoperative predictors were then established. Both models indicated good calibration, discrimination, and clinical usefulness. Finally, on the basis of the full nomogram model and clinical practice, we defined four risk intervals to facilitate clinical application.

It is well-known that lactate is produced by pyruvate during glycolysis, and its increase comes from an increase in production and a decrease in clearance. However, the parts that contribute more to the development of hyperlactatemia vary greatly from person to person (15, 18). In this study population, age, renal insufficiency, LVEF, cardiac surgery history, CPB time, and RBC transfusion were identified as independent predictors for POHL. Indeed, these factors were also found to be independently associated with renal impairment and pulmonary dysfunction after cardiac operations (19, 20). Thus, we speculate that POHL may act as an abnormal intermediate product and a causal link between clinical features and outcomes.

The history of previous cardiac surgery was identified as the most significant predictor for POHL after ECS in our analysis. Reentry procedures in redo cardiac surgery are technically demanding and carry elevated operative risk due to anatomical planes loss, injuries to numerous structures, and hemorrhage (21–23). Bianco et al. found that more blood product transfusion was required in reoperative patients, and speculated that transfusion requirements might be related to injuries upon reentry and prolonged operative and CPB time (24). In addition, patients undergoing reoperation often had older age and more comorbidities (24, 25). In this study, age was positively correlated to the peak lactate value. However, the results with regard to the correlation between age and elevated lactate were mixed in the literature, which may be caused by different measurement time points of lactate (10, 11).

Our results showed that the lower the preoperative LVEF, the higher risk of developing POHL, which was consistent with previous studies (8). It is well-known that low LVEF can affect tissue perfusion. Myocardial stunning caused by ischemia-reperfusion states, as a frequent consequence following CPB, may lead to decreased left ventricular function and thus can further aggravate the accumulation of lactate (26). In this study, renal insufficiency was another independent preoperative risk factor. This may be due to the fact that the kidney mostly relies on lactate as the gluconeogenic substrate, and renal insufficiency could affect the systemic clearance of lactate, giving rise to hyperlactatemia (27). In addition, patients undergoing chronic hemodialysis are more likely to be deficient in thiamine due to strict dietary control, which may cause pyruvate to shift to anaerobic metabolism (28).

The preoperative nomogram model comprising four preoperative factors mentioned above was moderately accurate in predicting POHL after ECS. These factors are simple and easily accessible in clinical practice. This nomogram allows patients to intuitively and easily understand their conditions. For clinicians, this may help to evaluate the risk of patients and formulate feasible plans.

Although this study was conducted in patients undergoing ECS, as expected, the independent association between CPB duration and POHL development was still significant, in line with previous studies (3, 10). Evans et al. reported that the
duration of CPB longer than 3 h was associated with 5.8-fold increased odds of POHL (13). The stress of cardiac surgery has been demonstrated to cause decreased pyruvate dehydrogenase quantity and activity and depletion of thiamine levels, resulting in hyperlactatemia (29, 30). Regrettably, Luger et al. found that the intravenous thiamine supplementation prior to cardiac surgery failed to significantly reduce postoperative blood lactate concentration (31). In addition, Mustafa et al. indicated that the CPB procedure decreased lactate clearance, which was possibly linked to the liver dysfunction in elective surgery (32). Moreover, microvascular thrombosis was found to be linked to cardiac surgery with CPB, and insufficient oxygen supply in the microcirculation area increased lactate levels (9). Without a doubt, the extension of CPB time will exacerbate this situation.

The loss of clotting factors and platelets induced by CPB leads to coagulation dysfunction, which may relate to an increased risk of bleeding (33). To some extent, more blood transfusion requirements always imply more blood loss during the operation. Moreover, hemodilution as a necessary part of the CPB process may further increase the possibility of demand for blood transfusion. In this study, the volume of RBC transfusion was also identified as an independent risk factor for POHL. It is undeniable that increasing oxygen delivery is the physiologic benefit of blood transfusion, and several studies have shown that RBC transfusion can improve tissue oxygenation and increase functional capillary density in the microcirculation (34, 35). However, increasing evidence suggested that massive transfusion of RBC increased the risk of adverse outcomes in cardiac surgical patients (36–38). Surgenor et al. indicated that RBC transfusion initiated a systemic inflammatory response, leading to local microvascular occlusion and tissue hypoxia (38). They also found that exposure to RBC transfusion during surgery was associated with low-output heart failure, which may have a relationship with hyperlactatemia (38). The results of randomized controlled trials also indicated that restrictive RBC transfusion strategy was safe in both adults and pediatric patients who underwent cardiac surgery, and it had obvious resources and economic advantages (39, 40).

In addition, limiting the effect of hemodilution on renal function was effective in reducing acute kidney injury rates (41). We speculate that it is reasonable to limit hemodilution and thus decrease transfusion requirements, which may reduce lactate levels due to the fact that renal injury may affect lactate metabolism. Of course, correction of preoperative anemia was also a feasible option for patients undergoing elective surgery to reduce intraoperative blood transfusion (42). Minimized CPB has also been reported to have beneficial effects on decreasing transfusion rate (43), which may be due to lower inflammatory response (44). Undeniably, skilled surgical operation with mature teamwork also plays an important part to reduce CPB and surgery time.

The full nomogram model involved four preoperative and two intraoperative predictors, showing a good prediction efficiency and clinical utility, and was well-validated in the independent cohort. Its character as a graphical prediction tool makes clinicians convenient to do a risk assessment and clinical intervention considerations. Moreover, the utilization of our models may help reduce the significant increase of lactate levels after ECS and, thus, may have a positive effect on reducing postoperative adverse outcomes.

Several measures have been reported to have an effect on alleviating POHL, such as minimal volume ventilation in robotically assisted cardiac surgery, continuous ultrafiltration through polyethersulfone membrane during CPB, and modified glucose–insulin–potassium regimen (45–47). There may exist a huge waste of labor and material resources if these measures are applied to all patients without selection, especially to those who are at very low risk. However, implementing these auxiliary interventions in patients who are identified as high risk by our risk models may be more effective and more cost-efficient for clinical application.

There are some limitations in this study that deserve mention. First, this was a retrospective observational study, and POHL was diagnosed on the basis of medical records. Despite having carefully reviewed all the records, we cannot ensure that all patients who developed POHL were included. Second, some possible risk factors for POHL after ECS were not available in this study, such as intraoperative hemodynamic data and the use of positive inotropic drugs. Nevertheless, the nomogram models performed well in discrimination, calibration, and clinical utility. Third, the records of POHL were limited within the first postoperative 12 h, which may underestimate the true incidence. However, this was in line with the main purpose of this study, as previous studies have indicated that early POHL was significantly associated with poorer prognosis.

CONCLUSION

In this study, we developed and validated two nomogram models to assess the probability of POHL in patients undergoing ECS. The full nomogram model incorporated both preoperative and intraoperative variables, and the preoperative nomogram model used only preoperative variables. Both nomogram models demonstrated good discrimination, calibration, and clinical utility. Based on the full nomogram model, four risk intervals were divided for better clinical practice. Risk assessment and targeted interventions based on the predictive models may be conducive to decreasing the incidence of POHL in patients undergoing ECS.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Ethical Committee of the Union Hospital (No. 0521), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.
AUTHOR CONTRIBUTIONS

DW, XH, AZ, and XD conceptualized and supervised the study. DW, JW, SL, FX, XL, AZ, and HW collected the clinical data. DW, SW, JW, SL, FX, XL, HW, and XH summarized all the data. DW, SW, JW, and SL drafted the manuscript. DW, SW, XH, AZ, and XD revised the final manuscript. All authors read and approved the final manuscript.

REFERENCES

1. Hajjar LA, Almeida JP, Fukushima JT, Rhodes A, Vincent JL, Osawa EA, et al. High lactate levels are predictors of major complications after cardiac surgery. J Thorac Cardiovasc Surg. (2013) 146:455–60. doi: 10.1016/j.jtcvs.2013.02.003
2. Govender P, Tosh W, Burt C, Fallet F. Evaluation of increase in intraoperative lactate level as a predictor of outcome in adults after cardiac surgery. J Cardiothorac Vasc Anesth. (2020) 34:877–84. doi: 10.1053/j.jvca.2019.10.039
3. Mallett J, Le Besnerais P, Cantoni M, Nafat P, Ruffenach A, Lessina A, et al. Frequency, risk factors, and outcome of hyperlactatemia after cardiac surgery. Chest. (2003) 123:1361–6. doi: 10.1378/chest.123.5.1361
4. Bakker J, Nijsten MW, Jansen TC. Clinical use of lactate monitoring in critically ill patients. Ann Intensive Care. (2013) 3:12. doi: 10.1186/2110-5820-3-12
5. Polonen P, Ruokonen E, Hippelainen M, Poyhonen M, Takala J. A prospective, randomized study of goal-oriented hemodynamic therapy in cardiac surgical patients. Anesth Analg. (2000) 90:1052–9. doi: 10.1097/00000539-200005000-00010
6. Mak NT, Iqbal S, de Varennes B, Khwaja K. Outcomes of post-cardiac surgery patients with persistent hyperlactatemia in the intensive care unit: a matched cohort study. J Cardiothorac Vasc Anesth. (2016) 11:33. doi: 10.1016/s1301-0616-0144-1-5
7. Haanschoten MC, Kreeftenberg HG, Arthur Bouwman R, van Straten AH, Buhrer WE, Soliman Hamada MA. Use of postoperative peak arterial lactate level to predict outcome after cardiac surgery. J Cardiothorac Vasc Anesth. (2017) 31:45–53. doi: 10.1053/j.jvca.2016.04.017
8. Ranucci M, Carboni G, Cotza M, Bianchi P, Di Dedda U, Aloisio T, et al. Hemodilution on cardiopulmonary bypass as a determinant of early postoperative hyperlactataemia. PLoS ONE. (2015) 10:e0126939. doi: 10.1371/journal.pone.0126939
9. Dixon B, Santamaria JD, Campbell DJ. Plasmaeogen activator inhibitor activity is associated with raised lactate levels after cardiac surgery with cardiopulmonary bypass. Crit Care Med. (2003) 31:1053–9. doi: 10.1097/01.ccm.0000055339.97331.db
10. Lopez-Delgado JC, Esteve F, Javirier C, Torrado H, Rodriguez-Castro D, Carrol ML, et al. Evaluation of serial arterial lactate levels as a predictor of hospital and long-term mortality in patients after cardiac surgery. J Cardiothorac Vasc Anesth. (2015) 29:1441–53. doi: 10.1053/j.jvca.2015.04.024
11. Svenmerker S, Haggemark S, Ostman M. What is a normal lactate level during cardiopulmonary bypass? Scand Cardiol J. (2006) 40:305–11. doi: 10.1080/1401430600992061
12. Inoue S, Kuro M, Furuya H. What factors are associated with hyperlactatemia after cardiac surgery characterized by well-maintained oxygen delivery and a normal postoperative course? A retrospective study. Eur J Anaesthesiol. (2001) 18:576–84. doi: 10.1016/S0952-818X(01)00033-0
13. Evans AS, Levin MA, Lin HM, Lee K, Weiner MM, Anyanwu A, et al. Prognostic value of hyperlactatemia and lactate clearance after mitral valve surgery. J Cardiothorac Vasc Anesth. (2018) 32:636–43. doi: 10.1053/j.jvca.2017.08.002
14. Kogan A, Preisman S, Bar A, Sternik L, Lavee J, Malachy A, et al. The impact of hyperlactatemia on postoperative outcome after adult cardiac surgery. J Anesth. (2012) 26:174–8. doi: 10.1007/s00540-011-1287-0

FUNDING

This study was supported by the National Natural Science Foundation of China (Grant nos. 81800413 and 81801586).

ACKNOWLEDGMENTS

The authors would like to thank Dr. John S. for help with the language.
31. Mustafa I, Roth H, Hanafiah A, Hakim T, Anwar M, Siregar E, et al. Effect of intravenous thiamine supplementation on blood lactate concentration prior to cardiac surgery: a double-blinded, randomised controlled pilot study. *Eur J Anaesthesiol.* (2015) 32:543–8. doi: 10.1097/EJA.0000000000000205

32. Mustafa I, Roth H, Hanafiah A, Hakim T, Anwar M, Siregar E, et al. Effect of cardiopulmonary bypass on lactate metabolism. *Intensive Care Med.* (2003) 29:1279–85. doi: 10.1007/s00134-003-1860-6

33. Ghadimi K, Levy JH, Welsby IJ. Perioperative management of the bleeding patient. *Br J Anaesth.* (2016) 117(suppl 3):iii18–iii30. doi: 10.1093/bja/aew358

34. Atasever B, van der Kuil M, Boer C, Vonk A, Schwarte L, Girbes AR, et al. Red blood cell transfusion compared with gelatin solution and no infusion after cardiac surgery: effect on microvascular perfusion, vascular density, hemoglobin, and oxygen saturation. *Transfusion.* (2012) 52:2452–8. doi: 10.1111/j.1537-2995.2012.03802.x

35. Bar S, Nguyen M, de Broca B, Bernard E, Dupont H, Guinot PG. Risk factors and determinants of intraoperative hyperlactatemia in major non-cardiac surgery. *J Clin Anesth.* (2021) 74:110359. doi: 10.1016/j.jclinane.2021.110359

36. Murphy GS, Hessel EA 2nd, Groom RC. Optimal perfusion during cardiopulmonary bypass: an evidence-based approach. *Anesth Analg.* (2009) 108:1394–417. doi: 10.1213/ane.0b013e3181875e2e

37. Karkouti K. Transfusion and risk of acute kidney injury in cardiac surgery. *Br J Anaesth.* (2012) 109(suppl 1):i29–38. doi: 10.1093/bja/aes422

38. Surgenor SD, DeFoe GR, Fillinger MP, Likosky DS, Groom RC, Clark C, et al. Intraoperative red blood cell transfusion during coronary artery bypass graft surgery increases the risk of postoperative low-output heart failure. *Circulation.* (2006) 114(1 Suppl):143–8. doi: 10.1161/CIRCULATIONAHA.105.002171

39. de Gast-Bakker DH, de Wilde RB, Hazekamp MG, Sojak V, Zwagginga JJ, Wolterbeek R, et al. Safety and effects of two red blood cell transfusion strategies in pediatric cardiac surgery patients: a randomized controlled trial. *Intensive Care Med.* (2013) 39:2070–9. doi: 10.1007/s00134-013-3085-7

40. Mazer CD, Whitlock RP, Fergusson DA, Hall J, Belley-Cote E, Connolly K, et al. Restrictive or liberal red-cell transfusion for cardiac surgery. *N Engl J Med.* (2017) 377:2133–44. doi: 10.1056/NEJMoa1711818

41. Ranucci M, Aloisi T, Carboni G, Ballotta A, Pistuddi V, Menicanti L, et al. Acute kidney injury and hemodilution during cardiopulmonary bypass: a changing scenario. *Ann Thorac Surg.* (2015) 100:95–100. doi: 10.1016/j.athoracsur.2015.02.034

42. Ionescu A, Sharma A, Kundnani NR, Mihalescu A, David VL, Bedreag O, et al. Intravenous iron infusion as an alternative to minimize blood transfusion in peri-operative patients. *Sci Rep.* (2020) 10:18403. doi: 10.1038/s41598-020-75335-2

43. Zangrillo A, Garozzo FA, Biondi-Zoccai G, Pappalardo F, Monaco F, Crivellari M, et al. Miniaturized cardiopulmonary bypass improves short-term outcome in cardiac surgery: a meta-analysis of randomized controlled studies. *J Thorac Cardiovasc Surg.* (2010) 139:1162–9. doi: 10.1016/j.jtcvs.2009.07.048

44. Curtis N, Vohra HA, Ohri SK. Mini extracorporeal circuit cardiopulmonary bypass system: a review. *Perfusion.* (2010) 25:115–24. doi: 10.1177/0267659110371705

45. Kesavuori R, Vento A, Lundbom N, Schramko A, Jokinen JJ, Raivio P. Minimal volume ventilation during robotically assisted mitral valve surgery. *Perfusion.* (2019) 34:705–13. doi: 10.1177/0267659119847917

46. Garcia-Camacho C, Marin-Paz AJ, Lagos-Prieto C, Abellán-Hervás MJ, Sainz-Otero AM. Continuous ultrafiltration during extracorporeal circulation and its effect on lactate metabolism: a randomized controlled trial. *PLoS ONE.* (2020) 15:e0242411. doi: 10.1371/journal.pone.0242411

47. Zhao K, Zhang Y, Li J, Cui Q, Zhao R, Chen W, et al. Modified glucose-insulin-potassium regimen provides cardioprotection with improved tissue perfusion in patients undergoing cardiopulmonary bypass surgery. *J Am Heart Assoc.* (2020) 9:e012376. doi: 10.1161/JAHA.119.012376

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Wang, Wang, Wu, Le, Xia, Li, Wang, Huang, Du and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.